Silvercrest Asset Management Group LLC Has $15.42 Million Stake in Evolent Health, Inc. (NYSE:EVH)

Silvercrest Asset Management Group LLC lifted its holdings in Evolent Health, Inc. (NYSE:EVH - Free Report) by 37.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,371,053 shares of the technology company's stock after purchasing an additional 372,793 shares during the period. Silvercrest Asset Management Group LLC owned 1.18% of Evolent Health worth $15,424,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Pilgrim Partners Asia Pte Ltd bought a new position in Evolent Health during the fourth quarter valued at about $26,000. R Squared Ltd acquired a new position in shares of Evolent Health during the 4th quarter valued at about $31,000. AlphaQuest LLC increased its holdings in shares of Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock valued at $34,000 after acquiring an additional 3,031 shares during the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock valued at $56,000 after acquiring an additional 2,358 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in Evolent Health in the 4th quarter worth approximately $61,000.

Evolent Health Stock Performance

EVH stock traded down $0.20 during trading on Friday, reaching $7.16. 432,637 shares of the stock were exchanged, compared to its average volume of 2,463,790. The stock has a 50 day simple moving average of $9.49 and a 200-day simple moving average of $10.71. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $840.70 million, a P/E ratio of -8.73 and a beta of 1.04. Evolent Health, Inc. has a twelve month low of $7.15 and a twelve month high of $33.63.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The technology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.02). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The business had revenue of $483.65 million during the quarter, compared to the consensus estimate of $460.15 million. During the same period last year, the firm earned $0.34 EPS. The company's quarterly revenue was down 24.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on EVH shares. Piper Sandler reiterated an "overweight" rating and set a $16.00 price target (down previously from $17.00) on shares of Evolent Health in a report on Friday, February 21st. Oppenheimer cut their target price on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a research report on Friday, January 24th. UBS Group upped their price target on shares of Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a report on Friday, May 9th. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 price target on shares of Evolent Health in a research report on Tuesday, May 13th. Finally, JMP Securities reissued a "market outperform" rating and set a $13.00 price objective on shares of Evolent Health in a research report on Monday, April 28th. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Evolent Health has a consensus rating of "Buy" and a consensus target price of $17.79.

Insider Activity at Evolent Health

In related news, CEO Seth Blackley purchased 55,225 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average price of $9.01 per share, with a total value of $497,577.25. Following the purchase, the chief executive officer now directly owns 762,217 shares in the company, valued at $6,867,575.17. This represents a 7.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, President Daniel Joseph Mccarthy acquired 11,040 shares of the company's stock in a transaction on Thursday, March 6th. The shares were bought at an average price of $9.01 per share, with a total value of $99,470.40. Following the completion of the purchase, the president now directly owns 389,004 shares of the company's stock, valued at approximately $3,504,926.04. This represents a 2.92% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 74,000 shares of company stock valued at $666,315 over the last quarter. 1.40% of the stock is owned by company insiders.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.